(Repeat story first published on Friday)
by Michael Erman
NEW YORK, June 25 (Reuters) – Infectious disease experts are also weighing the need for vaccination against the disease. Pfizer/BioNTech or Moderna mRNA for Americans vaccinated with Johnson & Johnson’s one-time vaccine due to increasing prevalence of communicable diseases Delta coronavirus variant
Some said they had already done so. Although there is no published data that combining the two different vaccines is safe and effective. or sponsored by US health regulators Canada and some European countries have now allowed people to get two shots of the COVID-19 vaccine.
The discussion highlights concerns about how preventable J&J shootings are compared to the delta variant first detected in India and is now spreading widely in several countries, said Rochelle Valenski, director of the Centers for Disease Control and Prevention. Disease (CDC) warns that Delta, which is also associated with more severe disease It could quickly become a dominant virus in the United States.
There is no significant data on how the J&J vaccine protects against the new variants. However, a UK study showed that two doses of the Pfizer/Bioentech or AstraZeneca vaccine were more protective against the variant. one dose is significant
Andy Slavitt, former senior adviser to US President Joe Biden̵7;s pandemic. The idea was brought up in his podcast this week. At least half a dozen prominent infectious disease experts say U.S. regulators. Problems need to be solved in a short time.
“There is no doubt that people who have been vaccinated with the J&J vaccine are less prone to disease,” said Professor Dr. Michael Lin from Stanford said. “From the principle of taking simple steps to prevent really bad results. This isn’t easy.”
The CDC does not recommend sponsors. and the agency’s advisors said at a public meeting this week. There is no significant evidence that vaccine protection is reduced.
Jason Gallagher, an infectious disease specialist at Temple University’s School of Pharmacy, recently received the Pfizer drug at a vaccine clinic in Philadelphia. for which he was vaccinated He received the J&J vaccine in a clinical trial in November.
Gallagher said he was concerned about Britain’s data. https://www.gov.uk/government/news/vaccines-highly-efficient-against-b-1-617-2-variant-after-2-doses show lower efficiency Delta Variant for One Dose Vaccine
“While the situation in the United States has improved greatly, the delta that spread … and rapidly occupied the United States. It looks a little more worrisome in terms of severe infections with single-use vaccines,” he said. “So I jumped on it.”
Hospitalization cases and deaths have declined in the United States, with 56% of the adult population being fully vaccinated.
J&J said it was testing whether the immune response from its vaccine could destroy the delta variant in the lab. but no information yet
Both mRNA vaccines showed an efficacy rate of approximately 95% in large US trials. Meanwhile, the J&J vaccine is 66% effective in preventing moderate to severe COVID-19 worldwide. When more invasive species
Dr Angela Rasmussen, a researcher at the University of Saskatchewan’s Organization for Vaccines and Infectious Diseases, said on Twitter that she received the Pfizer vaccine this week after receiving the J&J vaccine in April.
Rasmussen, who declined to be interviewed, encouraged Americans vaccinated J&J to talk to doctors about a possible second shooting.
“If you live in a community with low vaccination overall. I highly recommend you consider doing so,” she tweeted.
Dr. Peter Hotez, a vaccine specialist at Baylor College of Medicine, in a tweet said adding a second dose of J&J or one of the mRNA vaccines could offer broader protection. “But we need information and advice from the CDC-FDA.”
The US National Institute of Allergy and Infectious Diseases (NIAID) is conducting trials to determine the need to promote all currently permitted vaccinations with another dose of Moderna vaccine. Begel, a NIAID scientist, told Reuters that The agency hopes to have that information by September. To help inform regulators’ decisions regarding sponsors
As long as the number of cases remains low in the United States, J&J recipients should wait for more information, he said.
If delta variable-driven infections and hospitalizations increase dramatically, he said, “then decisions may be made without data, but now I think they deserve to wait.” (Reporting by Michael Erman Editing by Michael Erman) Caroline Humer and Bill Berkrot)